Oncogenic NFE2 induces immunosuppressive TGF-β in the bone marrow microenvironment of myeloproliferative diseases (P25*)

• Subject Area: Hematology, Oncology ; Immunology
• Term: since 2026
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 441891347

The transcription factor NFE2 constitutes an oncogene in myeloproliferative neoplasms (MPNs) and directly activates TGFB1 transcription, resulting in increased TGF-β production in both mouse and human B cells. This NFE2/TGF-β axis correlates with impaired B-cell maturation and immunosuppression. The project aims to define the molecular mechanisms linking NFE2 activity, TGF-β production, and immune dysfunction, particularly focusing on B cells. Using NFE2-modulated mouse models, gene reporter assays, and interactome studies, therapeutic targets within this pathway will be identified.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1479: Oncogene-driven immune escape (OncoEscape)
• Applicant Institution: Albert-Ludwigs-Universität Freiburg
• Project Heads: Professorin Dr. Heike L. Pahl; Professorin Dr. Marta Rizzi